Menu Search
Equities

Aethlon Medical Inc

EJU0:FRA

Aethlon Medical Inc

Actions
  • Price (EUR)0.308
  • Today's Change0.03 / 10.79%
  • Shares traded3.80k
  • 1 Year change-89.42%
  • Beta--
Data delayed at least 15 minutes, as of Jul 26 2024 07:12 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

  • Revenue in USD (TTM)0.00
  • Net income in USD-12.21m
  • Incorporated1991
  • Employees14.00
  • Location
    Aethlon Medical Inc11555 Sorrento Valley Road, Suite 203SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 459-7800
  • Websitehttps://www.aethlonmedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.